PSA: What This Test Actually Measures

What PSA Is, Biochemically

Prostate-specific antigen is a 33-kDa glycoprotein belonging to the human kallikrein gene family (hK3). Its biological job is simple: it liquefies the seminal coagulum after ejaculation so sperm can swim freely. The protein is a serine protease, meaning it cuts other proteins at specific amino acid sites. Almost all PSA enters seminal fluid at concentrations roughly one million times higher than those found in blood 1.

Small amounts leak into the bloodstream through the prostatic basement membrane. When the architecture of the prostate is disrupted (by cancer, infection, or simple enlargement) more PSA escapes into circulation. That leakage is what the blood test detects. PSA circulates in two forms: bound to protease inhibitors like alpha-1-antichymotrypsin, and unbound ("free"). The ratio between these forms carries diagnostic weight, a point explored below.

The test itself is a straightforward immunoassay. A lab technician measures total PSA concentration in nanograms per milliliter (ng/mL) from a standard blood draw. No fasting is required, though clinicians often advise avoiding ejaculation for 24 to 48 hours before the test because prostatic secretion temporarily raises serum levels 2.

Normal PSA Ranges and Age-Adjusted Cutoffs

A total PSA below 4.0 ng/mL has been the traditional "normal" threshold since the late 1980s. This single cutoff is an oversimplification. PSA concentrations rise naturally with age as the prostate grows, and they differ across racial groups.

Age-specific reference ranges proposed by Oesterling and colleagues offer more nuance 3:

| Age range | Suggested upper limit | |---|---| | 40 to 49 | 2.5 ng/mL | | 50 to 59 | 3.5 ng/mL | | 60 to 69 | 4.5 ng/mL | | 70 to 79 | 6.5 ng/mL |

Black men have higher baseline PSA on average and face a two-fold greater prostate cancer incidence, leading several expert panels to recommend screening discussions begin at age 40 in this population 4. The U.S. Preventive Services Task Force (USPSTF) assigns PSA-based screening a Grade C recommendation for men aged 55 to 69, advising shared decision-making 5.

A single number tells you little. Two readings separated by 12 months reveal a trend, and that trend (PSA velocity) is often more informative than the absolute value. A velocity exceeding 0.75 ng/mL per year in men with a PSA between 4 and 10 ng/mL doubled the odds of a cancer diagnosis at biopsy in the Baltimore Longitudinal Study of Aging 6.

What a High PSA Means (and What It Does Not)

A PSA above 4.0 ng/mL does not equal a prostate cancer diagnosis. The Prostate Cancer Prevention Trial found that 15.2% of men with PSA <4.0 ng/mL still had biopsy-detectable cancer, while roughly 75% of men with PSA between 4.0 and 10.0 ng/mL did not have cancer at all 7.

Common benign causes of elevated PSA include:

• Benign prostatic hyperplasia (BPH). The most frequent driver. A 60-gram prostate produces roughly twice the PSA of a 30-gram gland.
• Prostatitis. Acute bacterial prostatitis can push PSA above 10 ng/mL temporarily. Levels typically normalize within 6 to 8 weeks after antibiotic therapy.
• Recent ejaculation. A transient rise of 0.5 to 0.8 ng/mL may persist for 24 to 48 hours.
• Urinary retention or catheterization. Mechanical disruption of prostatic tissue causes leakage.
• Vigorous cycling. Perineal pressure can produce modest, short-lived elevations.

Cancer becomes more likely as PSA climbs. At levels above 10 ng/mL, the positive predictive value for clinically significant cancer approaches 50% to 60% 8. Multiparametric MRI of the prostate and confirmatory targeted biopsy have replaced the older sextant biopsy approach at many centers, reducing the number of unnecessary tissue samples.

Free PSA, PSA Density, and the Diagnostic Gray Zone

Total PSA between 4 and 10 ng/mL is sometimes called the "gray zone" because overlap between cancer and benign conditions is substantial. Three refinements help separate the two.

Free-to-total PSA ratio. Cancer cells produce PSA that binds more readily to serum proteins, leaving less free PSA in circulation. A free-to-total ratio below 10% is associated with a roughly 56% chance of cancer on biopsy, while a ratio above 25% drops that probability to around 8% 9.

PSA density. Dividing PSA by prostate volume (measured via transrectal ultrasound or MRI) adjusts for gland size. A density above 0.15 ng/mL/cc raises clinical suspicion for malignancy in men whose total PSA sits in the gray zone 10.

PHI and 4Kscore. The Prostate Health Index (PHI) combines total PSA, free PSA, and a precursor form called [-2]proPSA into a single score. In a multicenter validation study (N=892), PHI outperformed total PSA alone for detecting Gleason 7 or higher cancers (AUC 0.72 vs. 0.53) 11. The 4Kscore integrates four kallikrein markers with clinical variables and showed similar discrimination in U.S. cohorts.

These tools do not replace biopsy. They help clinicians and patients decide whether biopsy is warranted, reducing unnecessary procedures by an estimated 20% to 30%.

PSA Monitoring During Testosterone Replacement Therapy

Men on testosterone replacement therapy (TRT) receive repeated PSA measurements as a safety check. The Endocrine Society's 2018 clinical practice guideline recommends checking PSA at baseline, at 3 to 6 months after starting therapy, and then annually 12.

Exogenous testosterone stimulates prostate epithelial cells and can raise PSA. A meta-analysis of 26 randomized controlled trials found that TRT increased PSA by a mean of 0.3 to 0.5 ng/mL within the first 6 to 12 months, with levels plateauing thereafter 13. That modest bump rarely pushes men from a normal range into a danger zone on its own.

Red flags during TRT monitoring include:

• PSA rising above 4.0 ng/mL in a man who started below that threshold
• A confirmed increase exceeding 1.4 ng/mL within any 12-month period
• PSA velocity above 0.75 ng/mL per year on serial measurements

Any of these should trigger a urology referral, not an automatic biopsy. The American Association of Clinical Endocrinology (AACE) echoes this stepwise approach: evaluate first, intervene second 14.

"A PSA rise of half a point in the first six months of testosterone therapy is expected physiology, not pathology," states the Endocrine Society's 2018 guideline document. "Only sustained, progressive elevation warrants further investigation."

What a Low PSA Means

PSA below 1.0 ng/mL is not a clinical concern on its own. It typically reflects a smaller prostate volume, 5-alpha reductase inhibitor (5-ARI) use, or both.

Finasteride and dutasteride reduce PSA by approximately 50% within 6 to 12 months of use 15. Clinicians using PSA to screen men on a 5-ARI must double the measured value to estimate the "true" PSA. Missing this adjustment can mask a clinically meaningful rise.

After radical prostatectomy, PSA should fall to undetectable levels (<0.1 ng/mL within 6 weeks). Any subsequent detectable reading suggests biochemical recurrence and warrants imaging or salvage therapy discussion.

An interesting signal: very low baseline PSA predicts lower future cancer risk. In the Prostate Cancer Prevention Trial, men with PSA <0.5 ng/mL at age 60 had only a 2.4% probability of developing prostate cancer within 10 years, compared with 23.9% for men whose PSA was 2.0 to 3.0 ng/mL 16.

How to Lower PSA (Evidence-Based Approaches)

Lowering PSA is not a goal in itself. The aim is to address the underlying condition causing the elevation.

5-alpha reductase inhibitors. Finasteride 5 mg daily reduced PSA by a median of 50% over 4 years in the Prostate Cancer Prevention Trial (N=18,882) 17. Dutasteride produces a similar magnitude of suppression. These drugs shrink prostate volume, reducing both PSA output and obstructive urinary symptoms in men with BPH.

Treating infection. When prostatitis is the cause, a 4-to-6-week course of a fluoroquinolone or trimethoprim-sulfamethoxazole typically resolves the PSA elevation. Repeat testing should wait at least 6 weeks after completing antibiotics.

Weight management. Obesity is paradoxically associated with lower PSA (due to hemodilution from higher plasma volume) but higher-grade cancer at diagnosis 18. Losing excess weight does not predictably lower PSA, though it reduces hemodilution artifacts that can obscure a true rise.

Avoiding pre-test confounders. Abstaining from ejaculation for 48 hours and avoiding vigorous cycling before the blood draw produces the most accurate baseline reading.

No supplement has been shown in a randomized trial to lower PSA reliably. Saw palmetto, despite widespread use, failed to reduce PSA or urinary symptom scores in the STEP trial (N=369) published in JAMA 19.

PSA After Prostate Cancer Treatment

After treatment, PSA becomes a surveillance biomarker rather than a screening tool. The definitions of "detectable" vary by treatment modality.

Following radical prostatectomy, PSA should become undetectable (<0.1 ng/mL). The American Urological Association defines biochemical recurrence as a PSA that rises to 0.2 ng/mL or above on two consecutive measurements 20.

After radiation therapy, the Phoenix definition applies: biochemical failure equals the nadir PSA plus 2.0 ng/mL 21. Because radiation kills prostate cells gradually, the nadir may not occur until 18 to 24 months post-treatment.

"We follow PSA every 3 months for the first 2 years, then every 6 months through year 5, and annually thereafter," according to National Comprehensive Cancer Network (NCCN) prostate cancer surveillance guidelines.

Men on active surveillance for low-risk prostate cancer (Gleason 3+3, PSA <10 ng/mL, clinical stage T1c or T2a) undergo PSA testing every 6 months alongside periodic MRI and possible confirmatory biopsy. The goal is detecting reclassification early enough that curative treatment remains effective.

Limitations of PSA as a Biomarker

PSA is organ-specific, not cancer-specific. Every condition that affects the prostate (infection, enlargement, manipulation, malignancy) can change serum PSA. This lack of specificity drives a high false-positive rate and leads to biopsies that find no cancer.

The U.S. Preventive Services Task Force noted in its 2018 recommendation statement that for every 1,000 men aged 55 to 69 screened over 13 years, PSA-based screening prevents roughly 1.3 prostate cancer deaths but leads to approximately 155 false-positive results and roughly 17 to 50 overdiagnosed cancers 5.

Overdiagnosis (detecting cancers that would never cause symptoms or death) remains the central controversy. The ERSPC trial (N=182,160) demonstrated a 20% relative reduction in prostate cancer mortality with PSA screening at 13-year follow-up, but the number needed to screen to prevent one death was 781, and the number needed to diagnose was 27 22.

Newer biomarkers and imaging modalities are reducing these numbers. Multiparametric MRI combined with targeted biopsy can detect clinically significant cancer (Gleason 3+4 or higher) with greater sensitivity than systematic biopsy alone, as shown in the PRECISION trial (N=500), where MRI-targeted biopsy detected 38% clinically significant cancers compared with 26% for standard biopsy (P=0.005) 23.

When to Get Your PSA Checked

The timing of a first PSA test depends on risk factors.

For average-risk men, the USPSTF recommends an informed discussion about screening starting at age 55 5. The American Cancer Society suggests that conversation begin at age 50 for average-risk men and at 40 to 45 for men with a first-degree relative diagnosed with prostate cancer before age 65, or for Black men 24.

For men starting TRT, a pre-treatment PSA is mandatory per Endocrine Society guidelines. A baseline above 4.0 ng/mL (or above 3.0 ng/mL in high-risk men) warrants urology evaluation before initiating testosterone 12.

A baseline PSA at age 45 to 50 may also help risk-stratify future screening intensity. Men with PSA <1.0 ng/mL at age 50 can likely extend their screening interval to every 2 to 4 years, while those above 1.0 ng/mL may benefit from annual monitoring. The Endocrine Society's guideline for men on TRT mandates annual PSA indefinitely for the duration of therapy 12.